Is a 40 mg intramuscular triamcinolone injection appropriate for acute urticaria, and what short‑term systemic therapy should be added?

Intramuscular Triamcinolone for Acute Urticaria: Not Recommended

A 40 mg intramuscular triamcinolone injection is not appropriate for acute urticaria and should not be used. The evidence clearly shows that systemic corticosteroids, including intramuscular formulations, provide minimal to no benefit for acute urticaria while causing significant adverse effects.

Why This Approach Is Problematic

Limited Efficacy in Acute Urticaria

Recent high-quality evidence demonstrates that systemic corticosteroids add little value to antihistamine therapy:

• For patients with high antihistamine responsiveness (95.8% improvement rate), adding corticosteroids provides only a 2.2% absolute improvement (NNT = 45) 1
• For patients with moderate antihistamine responsiveness (17.5-64% improvement rate), corticosteroids provide 14-15% absolute improvement (NNT = 7), but this modest benefit is offset by harms 1
• Corticosteroids likely increase adverse events by 15% (NNH = 9), meaning you harm 1 patient for every 9 treated 1

Intramuscular Route Adds No Advantage

The FDA-approved indications for intramuscular triamcinolone include "control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment" 2. Acute urticaria is neither severe enough nor intractable—it is self-limited and responds to antihistamines. The intramuscular route provides no therapeutic advantage over oral corticosteroids while creating a depot effect that prolongs exposure to potential side effects.

Guidelines Do Not Support This Practice

The British Journal of Dermatology guidelines state that oral corticosteroids may shorten the duration of acute urticaria (e.g., prednisolone 50 mg daily for 3 days) but emphasize this is for selected cases 3. Importantly, long-term corticosteroids should not be used in chronic urticaria (Strength of recommendation A) 3. There is no mention of intramuscular corticosteroids as appropriate therapy.

What Should Be Done Instead

First-Line: High-Dose Non-Sedating H1-Antihistamines

Start with a second-generation H1-antihistamine at standard dose, then rapidly up-dose if needed:

• Cetirizine 10 mg, levocetirizine 5 mg, fexofenadine 180 mg, desloratadine 5 mg, or loratadine 10 mg once daily 33
• If inadequate response after 2-4 weeks (or earlier if symptoms are intolerable), increase up to 4-fold the standard dose 44
• This approach is safe and supported by Quality of evidence III, Strength of recommendation C 3

Why Antihistamines Work Better

• Cetirizine has the shortest time to maximum concentration, making it ideal when rapid availability is needed 3
• Up-dosing antihistamines is more effective than adding corticosteroids for most patients 15
• Intravenous second-generation H1-antihistamines (in ED settings) show superior outcomes compared to first-generation antihistamines with lower risk of return visits (OR 0.31) and fewer adverse events (OR 0.24) 5

When to Consider Short-Course Oral Corticosteroids

Only consider oral corticosteroids (NOT intramuscular) in highly selected cases:

• Patient has severe, intolerable symptoms despite antihistamine therapy
• Use prednisolone 50 mg daily for 3 days maximum in adults 3
• Recognize that even this provides marginal benefit and increases adverse effects by 15% 1

Avoid Common Pitfalls

• Do not use intramuscular corticosteroids—they create prolonged exposure without added benefit
• Do not prescribe epinephrine auto-injectors for uncomplicated acute urticaria without evidence of anaphylaxis 6
• Avoid NSAIDs and alcohol during acute episodes as they can worsen urticaria 3
• Do not delay escalation to appropriate therapy—if antihistamines fail at 4-fold dosing after 2-4 weeks, consider omalizumab (for chronic cases) rather than prolonging ineffective treatment 7

The Bottom Line

The provider's decision to give 40 mg intramuscular triamcinolone lacks clinical evidence and exposes the patient to unnecessary risks. Acute urticaria is a self-limited condition best managed with high-dose non-sedating antihistamines. If systemic corticosteroids are absolutely necessary, use a short 3-day course of oral prednisolone—never intramuscular depot formulations. The intramuscular route provides no therapeutic advantage while creating prolonged corticosteroid exposure that increases the risk of adverse effects including hyperglycemia, mood changes, insomnia, and immunosuppression.